Rezolute - Common (Nv) (RZLT) closed at $3.64 on November 5, 2026, down 8.1% from the previous close, on volume of 1,150,801 shares (30-day average 1,548,118).
Data as of November 5, 2026.
5-Nov-2026
Rezolute GAAP EPS of -$0.18 in-line
Seeking Alpha News (Fri, 6-Nov 12:23 AM ET)
Rezolute Reports First Quarter Fiscal 2027 Financial Results and Provides Business Update
Globe Newswire (Thu, 5-Nov 4:05 PM ET)
Rezolute to Participate in Upcoming Investor Conferences
Globe Newswire (Mon, 2-Nov 7:30 AM ET)
Globe Newswire (Wed, 14-Oct 4:05 PM ET)
Globe Newswire (Mon, 5-Oct 7:00 AM ET)
Globe Newswire (Thu, 24-Sep 4:05 PM ET)
Globe Newswire (Wed, 9-Sep 7:00 AM ET)
Market Chameleon (Wed, 25-Mar 7:11 AM ET)
Rezolute Faces Regulatory Scrutiny After Lead Drug Failure Prompts 90% Share Plunge
Market Chameleon (Tue, 23-Dec 6:06 AM ET)
Rezolute Faces Investor Scrutiny as Phase 3 Drug Failure Triggers Sharp Reaction and Investigation
Market Chameleon (Wed, 17-Dec 6:47 AM ET)
Rezolute Inc is a late-stage rare disease company focused on developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism. Its main clinical asset, Ersodetug, is a potential treatment for refractory hypoglycemia caused by multiple forms of hyperinsulinism. The company has a single reportable segment, which includes all of its activities as a clinical-stage biopharmaceutical company.
Rezolute - Common (Nv) trades on the NASDAQ stock market under the symbol RZLT.
As of November 5, 2026, RZLT stock price declined to $3.64 with 1,150,801 million shares trading.
RZLT has a beta of 1.39, meaning it tends to be more sensitive to market movements. RZLT has a correlation of 0.01 to the broad based SPY ETF.
RZLT has a market cap of $352.07 million. This is considered a Small Cap stock.
In the last 3 years, RZLT traded as high as $11.46 and as low as $.72.
The top ETF exchange traded funds that RZLT belongs to (by Net Assets): VTI, IWM, VXF, IWN, DFAS.
RZLT has underperformed the market in the last year with a return of -59.1%, while the SPY ETF gained +9.7%. In the last 3 month period, RZLT fell short of the market, returning -26.8%, while SPY returned -4.7%. However, in the most recent 2 weeks RZLT has outperformed the stock market by returning -1.6%, while SPY returned -5.2%.
RZLT support price is $3.75 and resistance is $4.17 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RZLT shares will trade within this expected range on the day.
